Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Royalty Pharma buys Eisai's ex-Japanese royalties on tazemetostat for $330mm

Executive Summary

Eisai Co. Ltd. sold Royalty Pharma its share of all future royalties on worldwide sales (outside of Japan) of tazemetostat, an oral EZH2 inhibitor for both solid tumors and hematological malignancies, in-licensed from Epizyme Inc. under a 2011 deal.
Deal Industry
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies